Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. ETF
  3. NEUP
NEUP logo

NEUP

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewTechnicalNews
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

NEUP News

Neuphoria Urges Shareholders to Support Director Nominees for Maximum Value

Dec 08 2025Newsfilter

Nasdaq Rises 1%; Procter & Gamble Reports Positive Earnings

Oct 24 2025Benzinga

Tuesday's Major Stock Market Highlights: Morning News Summary!

Oct 21 2025TipRanks

What Caused Neuphoria Therapeutics Stock (NEUP) to Drop 65% Today?

Oct 21 2025TipRanks

Neuphoria Therapeutics Shares Progress on AFFIRM-1 Phase 3 Trial Assessing BNC210 for Treating Acute Social Anxiety Disorder

Oct 20 2025Newsfilter

Neuphoria Therapeutics Inc. Sees Decrease in Annual Loss

Sep 30 2025NASDAQ.COM

IMRX Rises on Pancreatic Cancer Findings, PEPG Achieves DM1 Splicing Correction Milestone, CLPT Under Observation

Sep 25 2025NASDAQ.COM

Maxim Group Reaffirms Buy Rating for Neuphoria Therapeutics and Increases Price Target to $35

Sep 11 2025Benzinga

Neuphoria Therapeutics Achieves Target Enrollment for Phase 3 AFFIRM-1 Study of BNC-210 in Treating Social Anxiety Disorder (SAD)

Sep 04 2025Newsfilter

HC Wainwright & Co. Affirms Buy Rating for Neuphoria Therapeutics, Keeps $21 Price Target Intact

Aug 26 2025Benzinga

Neuphoria to Present at the American Society of Clinical Psychopharmacology (ASCP) 2025 Annual Meeting

May 27 2025Newsfilter

Neuphoria Therapeutics Inc. Reports Q1 2025 Progress and Upcoming Milestones for BNC210 and MK-1167 Programs

May 20 2025NASDAQ.COM

Neuphoria Provides First Quarter 2025 Business Updates

May 20 2025Newsfilter

Neuphoria Provides a Review of 2024 and Highlights 2025 Plans

Apr 15 2025Newsfilter

Neuphoria Therapeutics to Ring the Nasdaq Opening Bell on March 3rd, 2025

Mar 03 2025Newsfilter

Neuphoria Therapeutics shares surge on $15M Merck payment By Investing.com

Feb 12 2025Investing.com